Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Published:2007-10-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Schulz Holger¹,Bohlius Julia¹,Skoetz Nicole¹,Trelle Sven²,Kober Thilo³,Reiser Marcel⁴,Dreyling Martin⁵,Herold Michael⁶,Schwarzer Guido⁷,Hallek Michael⁴,Engert Andreas¹

Affiliation:

1. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924

2. University of Bern; Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine; Finkenhubelweg 11 Bern Switzerland CH-3012

3. Smiling Press Productions; 3 Ulm Street Scullin Australia ACT 2614

4. University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn; Kerpener Str. 62 Cologne Germany 50924

5. Klinikum der Universität München-Großhadern; Medizinische Klinik III; München Germany 81366

6. 2. Medizinische Klinik, Helios Klinikum Erfurt; Medical Clinic Hematology/Oncology; Nordhäuser Straße 74 Erfurt Germany 99089

7. German Cochrane Center; Department of Medical Biometry and Statistics; University Medical Center Stefan-Meier-Str. 26 Freiburg Germany D-79104

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003805.pub2/fullpdf

Reference67 articles.

1. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Forstpointner;Blood,2004

2. Herold M Pasold R Srock S Neser S Niederwieser D Neubauer A Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL) ASH Annual Meeting Abstracts 2004 584

3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood,2005

4. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG);Lenz;J Clin Oncol,2005

5. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis;Annals of Hematology;2023-08-08

2. A Rare Case of Nodular Mantle Cell Lymphoma of the Gastrointestinal Tract Discovered During a Routine Colonoscopy With a Positive Response to R-CHOP Chemotherapy Regimen;Cureus;2023-07-26

3. Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort;The Oncologist;2023-06-27

4. FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects;Cancers;2023-02-07

5. Assistência Farmacêutica a Pacientes Oncológicos em Uso de Anticorpos Monoclonais em um Hospital de Referência do Oeste de Santa Catarina;Revista Brasileira de Cancerologia;2022-08-16